{"id":22010,"date":"2025-07-11T13:30:50","date_gmt":"2025-07-11T10:30:50","guid":{"rendered":"https:\/\/canatu.com\/?p=22010"},"modified":"2025-07-11T15:23:12","modified_gmt":"2025-07-11T12:23:12","slug":"canatu-receives-customer-approval-for-its-cnt100-semi-reactor-and-post-processing-equipment-enabling-mass-production-of-advanced-euv-pellicles","status":"publish","type":"post","link":"https:\/\/canatu.com\/company\/carbon-age-news\/canatu-receives-customer-approval-for-its-cnt100-semi-reactor-and-post-processing-equipment-enabling-mass-production-of-advanced-euv-pellicles\/","title":{"rendered":"Canatu receives customer approval for its CNT100 SEMI reactor and post-processing equipment, enabling mass production of advanced EUV pellicles"},"content":{"rendered":"\n

VANTAA, FINLAND<\/strong> \u2013 July 11, 2025 \u2014 Canatu Plc (\u201cCanatu\u201d) has received Site Acceptance Test (SAT) approval for its first CNT100 SEMI reactor and for the related post-processing peripherals, shipped to a semiconductor customer in September 2024. The equipment successfully passed the extensive tests conducted on-site at the customer\u2019s premises and met the stringent technical requirements and specifications defined in the acceptance criteria. This confirms the CNT100 SEMI reactor\u2019s readiness for mass production of CNT pellicle membranes.<\/p>\n\n\n\n

\n

“As far as we know, this marks the world\u2019s first CNT reactor qualification for EUV pellicle manufacturing. Receiving SAT approval is a significant milestone for Canatu and for advanced semiconductor technologies. For the first time, our CNT100 SEMI reactor and its peripherals have been approved by the customer and are now ready for CNT pellicle membrane mass production. We sincerely thank everyone involved for their outstanding collaboration, which made this historical achievement possible.”<\/p>\nJuha Kokkonen, CEO of Canatu<\/cite><\/blockquote>\n\n\n\n

The next step for the customer is to secure final approval for the ready CNT pellicle product and the complete manufacturing line, before pilot and risk mass production can begin. This phase would initiate the mass production of CNT pellicle membranes, generating non-recurring revenue from technology licensing, as well as recurring revenue from royalties on CNT pellicle sales, and from reactor consumables.<\/p>\n\n\n\n

Site Acceptance Test (SAT) means that the equipment is tested on-site after Factory Acceptance Test (FAT) to ensure the reactor and peripherals operate as intended in real use conditions. The SAT process included several output and product quality tests. With the SAT approval, Canatu\u2019s CNT100 SEMI reactor and peripherals are now ready for mass production.<\/p>\n\n\n\n

Demand for advanced semiconductors is accelerating due to the rapid growth of artificial intelligence. EUV (Extreme Ultraviolet) lithography is gaining traction, especially for sub-7 nanometer chips\u2014the fastest-growing segment. Canatu is well-positioned to support this shift with its advanced CNT pellicle membranes, which outperform traditional composite pellicles. These membranes offer higher EUV transmission and greater thermal resistance, enabling them to withstand the extreme heat loads of 600W EUV lithography tools used to produce the most advanced chips.<\/p>\n\n\n\n

Additional information:<\/strong><\/p>\n\n\n\n

CEO Juha Kokkonen, tel. +358 405 430 367<\/p>\n\n\n\n

Board member Tuomo V\u00e4h\u00e4passi, tuomo.vahapassi@lifeline-spac1.com<\/p>\n\n\n\n

Certified Adviser<\/strong><\/p>\n\n\n\n

DNB Carnegie Investment Bank AB (publ), tel. +46 (0)73 856 42 65<\/p>\n\n\n\n

About Canatu<\/strong> <\/p>\n\n\n\n

Canatu (CANATU, Nasdaq First North, Finland) is a fast-growing deep technology company creating advanced carbon nanotubes (Canatu CNTs), related products, and manufacturing equipment for the semiconductor, automotive, and medical diagnostics industries. Canatu partners with forerunner companies, together transforming products for better tomorrows with nano carbon.  <\/p>\n\n\n\n

Canatu’s versatile platform technology has broad potential applications. Its current core includes CNT membranes for extreme ultraviolet (EUV) processes in the semiconductor industry, enabling the manufacturing of the most advanced chips, as well as film heaters for advanced driver-assistance systems (ADAS) in the automotive industry. Additionally, electrochemical sensors for medical diagnostics are in the development phase. Canatu\u2019s patented CNT reactors and Dry DepositionTM<\/sup> method yield clean and pristine CNTs. The company operates through two business models: selling CNT products directly, as well as selling CNT reactors and licensing the related technology so that customers can produce CNT products under a limited license.  <\/p>\n\n\n\n

Headquartered in Finland, Canatu also operates in the US, Japan, and Taiwan. Founded in 2004 as a spin-off from Aalto University\u2019s Nanomaterials Group, Canatu currently has around 140 employees representing 35 nationalities, with 20 percent holding or pursuing doctorates. Discover more at www.canatu.com<\/a> and follow us on LinkedIn<\/a>. <\/p>\n\n\n\n\n

\n

Media relations<\/h2>\n
\n
\n \n \n \n \"Mari\n<\/picture> <\/div>\n
\n
Mari Makkonen<\/div>\n
VP, IR, Communications and Marketing<\/div>\n mari.makkonen@canatu.com<\/a>\n +358 504 422 343<\/a>\n <\/div>\n <\/div>\n<\/div>\n\n\n
\n
\n
\n

Send us a message<\/h3>\n